Tracking Infections in Blood Cancer Patients on Bispecific Antibody Treatment
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy, Infections clinical trials.
This study follows adults with blood cancers (like multiple myeloma or lymphoma) who are starting a newer type of immunotherapy called bispecific antibodies. Researchers want to understand what infections might develop during this treatment and how often they occur, which could help doctors better protect patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have been diagnosed with a blood cancer (such as multiple myeloma, non-Hodgkin lymphoma, or similar)
- Have started bispecific antibody treatment within the last 30 days
- Be able to understand and sign a consent form
- Be willing to have infections tracked for up to one year of treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks infections in people who receive CAR-T cell therapy for certain blood cancers like multiple myeloma and B-cell non-Hodgkin lymphoma. It aims to understand how often infections happen and how to prevent them.
This study looks at using bispecific antibodies (a type of immune therapy) to help people with multiple myeloma who have relapsed or stopped responding to other treatments. It aims to better understand why some patients may not respond or relapse after this targeted therapy.
This study looks at how well newer antibody treatments work for B-cell non-Hodgkin lymphoma. It uses blood and tissue samples to learn more about the treatment, which may help guide better care.
This trial tests if a medicine called IgPro20 can help prevent infections in people with multiple myeloma who have low antibody levels and are being treated with a bispecific antibody. If you have relapsed or refractory myeloma and have recently started a bispecific antibody, this study might help protect you from getting serious infections.
This trial tests an experimental BCMA bispecific antibody called linvoseltamab for people with multiple myeloma that has returned after BCMA CAR T-cell therapy. The goal is to see if this new approach can still fight the cancer effectively.
This trial compares two treatments—antibiotics or immunoglobulin (a blood product with infection-fighting antibodies)—to see which better prevents infections in people with certain blood cancers like CLL, multiple myeloma, or non-Hodgkin's lymphoma.
Hear when a new Severe Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.